Follow-up survey and endpoints
TB, death
DISEASES, ADVERSE EVENT, PULMONARY TUBERCULOSIS
All participants including untreated controls were followed up for 24 months. At quarter follow-up, participants were investigated of suspected symptoms through door-to-door or telephone survey. At annual follow-up, participants were invited for investigation on suspected symptoms and chest DR examination. Participants with evidence of suspected TB were transferred to the local Center for Diseases Control and Prevention for final diagnosis. Three sputum samples were collected from each participant for sputum smear, culture and GeneXpert MTB/RIF assay. On the basis of National Health Industry Standard on Diagnosis for Pulmonary Tuberculosis (WS288-2017) [Treatment completion, permanent discontinuation, or death from any cause were also analysed. Treatment completion was defined as completion of ≥11 of 12 doses and was comprehensively assessed by pill counts and drug registration. AEs and study drug-related side-effects were graded by researchers according to the Common Terminology Criteria for Adverse Events (CTC-AE, version 4.0). The attribution of drug-related side-effects was co-determined by two external physicians using a scale ranging from unrelated to definitely related (Supplementary Table S2).Temporary or permanent discontinuation was judged by physicians and principal investigators based on clinical evaluation. For permanently discontinued participants, follow-up lasted until the end of two-year follow-up.